You are here: Industry Insights > Molnupiravir

News List

Molnupiravir: Merck’s Covid-19 antiviral less effective in new analysis Pharmaceutical-Technology
November 30, 2021
Merck has provided updated data on its Covid-19 antiviral, molnupiravir, that shows the antiviral to be significantly less effective against the virus than previously thought.
EMA receive marketing authorisation application for molnupiravir PharmaTimes
November 26, 2021
The use of molnupiravir in COVID-19 cases aims to reduce the pressure on hospitals, in turn reducing the risk of patients developing more severe symptoms of the virus.
EMA supports molnupiravir prior to formal authorisation PharmaTimes
November 23, 2021
The European Medicines Agency (EMA) has issued emergency use advice (EUA) supporting a decision by national authorities for the possible early use of Merck's molnupiravir, the oral antiviral drug for the treatment of patients with COVID-19.
Merck and Ridgeback's molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world WorldPharmaNews
November 16, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA)...
Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval AmericanPharmaceuticalReview
November 12, 2021
Merck and Ridgeback Biotherapeutics announced that the Japanese government will purchase, upon authorization or approval, approximately 1.6 million courses of molnupiravir (MK-4482, EIDD-2801)...
UK grants world-first approval to Covid-19 pill molnupiravir Pharmaceutical-Technology
November 05, 2021
The first oral antiviral to treat Covid-19, Merck and Ridgeback Biotherapeutics’ molnupiravir, has been approved by the UK drugs regulator.
UK Authorizes Merck, Ridgeback’s Oral COVID Antiviral Molnupiravir ContractPharma
November 05, 2021
Merck and Ridgeback Biotherapeutics received authorization in the UK for molnupiravir (MK-4482, EIDD-2801), the first oral antiviral medicine authorized for the treatment of mild-to-moderate COVID-19...
Merck and MPP sign licence deal for oral antiviral Covid-19 drug Pharmaceutical-Technology
October 29, 2021
Merck (MSD) and the Medicines Patent Pool (MPP) have entered a voluntary licencing agreement to offer affordable international access for the former’s experimental oral antiviral, molnupiravir (MK-4482/EIDD-2801), to treat Covid-19.
Everest Organics starts API production for Merck anti-COVID pill CPhIonline
October 15, 2021
Manufacturer starts development of API for molnupiravir, which is set to become world’s first oral treatment against coronavirus
Merck Canada Initiates Rolling Submission to Health Canada for Molnupiravir, an Investigational Oral Therapeutic Agent for the Treatment of COVID-19 firstwordpharma
August 16, 2021
Merck, known as MSD outside the United States and Canada, today announced the initiation of a rolling submission to Health Canada for molnupiravir, an investigational twice daily oral antiviral agent currently in trials as a potential treatment.

Previous page 1 2 3 4 Next page